Renaissance Technologies LLC Invests $3.17 Million in Establishment Labs Holdings Inc. $ESTA

Key Points

• Renaissance Technologies initiated a $3.17 million position in Establishment Labs, purchasing 55,800 shares, while institutional investors and hedge funds collectively own 72.91% of the company.
• Analyst sentiment remains favorable, with seven Buy ratings and a consensus price target of $100.25; several firms recently raised their targets, including TD Cowen to $117 and BTIG to $103.
• Establishment Labs reported quarterly revenue of $67.54 million, up 31.7% year over year and above estimates, but its $0.39-per-share loss exceeded expectations. Shares opened at $77.42, below the analyst consensus target, as profitability remains a concern.

Renaissance Technologies LLC purchased a new position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 55,800 shares of the company's stock, valued at approximately $3,168,000. Renaissance Technologies LLC owned approximately 0.19% of Establishment Labs as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Simplify Asset Management Inc. boosted its stake in Establishment Labs by 92.1% during the 4th quarter. Simplify Asset Management Inc. now owns 72,894 shares of the company's stock worth $5,313,000 after purchasing an additional 34,946 shares during the last quarter. Sigma Planning Corp grew its holdings in shares of Establishment Labs by 325.5% during the first quarter. Sigma Planning Corp now owns 20,424 shares of the company's stock worth $1,160,000 after buying an additional 15,624 shares in the last quarter. SG Americas Securities LLC raised its position in shares of Establishment Labs by 134.3% in the first quarter. SG Americas Securities LLC now owns 37,928 shares of the company's stock valued at $2,154,000 after buying an additional 21,742 shares during the last quarter. AlTi Global Inc. purchased a new position in shares of Establishment Labs in the first quarter worth about $842,000. Finally, Sofinnova Investments Inc. lifted its stake in shares of Establishment Labs by 163.0% in the fourth quarter. Sofinnova Investments Inc. now owns 28,366 shares of the company's stock worth $2,067,000 after buying an additional 17,579 shares in the last quarter. 72.91% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ESTA has been the topic of a number of recent research reports. Citigroup boosted their price target on shares of Establishment Labs from $76.00 to $92.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 8th. Needham & Company LLC raised their target price on shares of Establishment Labs from $86.00 to $95.00 and gave the stock a "buy" rating in a research note on Thursday. BTIG Research boosted their target price on Establishment Labs from $96.00 to $103.00 and gave the stock a "buy" rating in a report on Thursday. Canaccord Genuity Group set a $105.00 price target on Establishment Labs in a research report on Thursday. Finally, TD Cowen increased their price target on Establishment Labs from $95.00 to $117.00 and gave the company a "buy" rating in a report on Monday, August 3rd. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $100.25.

Establishment Labs Trading Down 2.1%

Shares of ESTA stock opened at $77.42 on Friday. The company has a current ratio of 2.96, a quick ratio of 1.91 and a debt-to-equity ratio of 16.82. Establishment Labs Holdings Inc. has a twelve month low of $33.35 and a twelve month high of $97.59. The company's 50-day moving average price is $86.43 and its 200-day moving average price is $74.25. The stock has a market cap of $2.28 billion, a price-to-earnings ratio of -59.10 and a beta of 1.07.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.05). Establishment Labs had a negative return on equity of 205.79% and a negative net margin of 15.82%.The firm had revenue of $67.54 million for the quarter, compared to analyst estimates of $65.79 million. During the same quarter in the previous year, the business posted ($0.57) earnings per share. Establishment Labs's revenue for the quarter was up 31.7% on a year-over-year basis. As a group, equities analysts predict that Establishment Labs Holdings Inc. will post -1.07 earnings per share for the current year.

Establishment Labs News Roundup

Here are the key news stories impacting Establishment Labs this week:

• Positive Sentiment: JPMorgan raised its price target on Establishment Labs from $84 to $95 and maintained an Overweight rating, implying substantial upside from the current trading level. Benzinga analyst report
• Positive Sentiment: BTIG increased its price target from $96 to $103 and reiterated a Buy rating, while Needham lifted its target from $86 to $95 and also maintained a Buy rating. These revisions suggest analysts remain optimistic about the company’s growth prospects. The Fly analyst report
• Positive Sentiment: Establishment Labs reported quarterly revenue of $67.54 million, exceeding the $65.79 million analyst estimate and increasing 31.7% year over year. The company also projected 2026 revenue of $269 million to $271 million, above the $267.5 million consensus estimate. Zacks quarterly results report
• Neutral Sentiment: Management indicated that minimally invasive procedures now account for approximately 15% of sales, highlighting potential for longer-term market expansion, but investors may remain focused on the company’s path to profitability. Seeking Alpha revenue outlook report
• Negative Sentiment: The company reported a second-quarter loss of $0.39 per share, wider than the $0.34 expected loss, though the result improved from a $0.57 loss in the year-ago quarter. The earnings miss, continued negative margins, and lack of profitability are likely weighing on the shares. MarketBeat earnings report

Establishment Labs Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company's proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company's flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source